Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia

被引：0
|
作者：
Yvyin Zhang
Peihong Wang
Yang Wang
Yang Shen
机构：
[1] State Key Laboratory of Medical Genomics,Shanghai Institute of Hematology
[2] National Research Center for Translational Medicine (Shanghai),Department of Hematology
[3] Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,undefined
[4] Guangzhou First People’s Hospital,undefined
[5] School of Medicine,undefined
[6] South China University of Technology,undefined
来源：
Biomarker Research | / 11卷
关键词：
Sitravatinib; -ITD; AML; Gilteritinib; Drug resistance; -ITD-F691L; FL; FGF2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia
    Xu, B.
    Zhao, Y.
    Wang, X.
    Gong, P.
    Ge, W.
    LEUKEMIA, 2017, 31 (04) : 913 - 921
  • [22] MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia
    B Xu
    Y Zhao
    X Wang
    P Gong
    W Ge
    Leukemia, 2017, 31 : 913 - 921
  • [23] Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations
    Wei, Tian-Hua
    Wang, Zi-Xuan
    Lu, Meng-Yi
    Xu, Yu-Jing
    Yang, Jin
    Ni, Xing-Feng
    Cheng, Yang
    Zhang, Meng-Yuan
    Liu, Jia-Chuan
    Li, Qing-Qing
    Cai, Jiao
    Chen, Zi-Jun
    Kang, Ji-Bo
    Li, Nan
    Dai, Wei-Chen
    Ding, Ning
    Yu, Yan-Cheng
    Leng, Xue-Jiao
    Xue, Xin
    Wang, Xiao-Long
    Sun, Shan-Liang
    Yang, Ye
    Li, Nian-Guang
    Shi, Zhi-Hao
    JOURNAL OF MEDICINAL CHEMISTRY, 2024,
  • [24] Acute Kidney Injury Possibly Due to the FLT3 Inhibitor Gilteritinib in a Patient with Refractory Acute Myeloid Leukemia: a Case Report
    Yutaka Shimazu
    Munehiro Ucikawa
    Mizuho Furuichi
    Masaharu Nohgawa
    SN Comprehensive Clinical Medicine, 4 (1)
  • [25] Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
    Zhang, Weiguo
    Yu, Guopan
    Zhang, Hongying
    Basyal, Mahesh
    Ly, Charlie
    Yuan, Bin
    Ruvolo, Vivian
    Piya, Sujan
    Bhattacharya, Seemana
    Zhang, Qi
    Borthakur, Gautam
    Battula, Venkata L.
    Konopleva, Marina
    Rice, William G.
    Andreeff, Michael
    HAEMATOLOGICA, 2023, 108 (06) : 1500 - 1514
  • [26] Discovery of the FLT3 inhibitor gilteritinib as a novel therapeutic strategy to overcome ALK-TKI resistance
    Mizuta, Hayato
    Takemoto, Ai
    Takagi, Satoshi
    Simizu, Siro
    Nishio, Makoto
    Fujita, Naoya
    Katayama, Ryohei
    CANCER SCIENCE, 2022, 113 : 1261 - 1261
  • [27] FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
    Pulte, E. Dianne
    Norsworthy, Kelly J.
    Wang, Yaping
    Xu, Qing
    Qosa, Hisham
    Gudi, Ramadevi
    Przepiorka, Donna
    Fu, Wentao
    Okusanya, Olanrewaju O.
    Goldberg, Kirsten B.
    De Claro, R. Angelo
    Farrell, Ann T.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3515 - 3521
  • [28] The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia
    Carvajal, Luis A.
    McKeown, Michael R.
    Hood, Tressa
    Guo, Linlin
    Lin, Charles Y.
    DiMartino, Jorge F.
    BLOOD, 2023, 142
  • [29] Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia
    Fathi, Amir Tahmasb
    Arevalo, Mabel
    Gutierrez, Sonia
    Molero, Antonieta
    Sacilotto, Natalia
    Limon, Ana E.
    Faller, Douglas V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib
    Wang, Peihong
    Zhang, Yvyin
    Xiang, Rufang
    Yang, Jie
    Xu, Yanli
    Deng, Tingfen
    Zhou, Wei
    Wang, Caixia
    Xiao, Xinhua
    Wang, Shunqing
    CANCER RESEARCH, 2024, 84 (06) : 905 - 918
12345